Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase 1b/2 Study Assessing the Safety and Efficacy of Mitazalimab in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Next Previous
Trial Profile

An Open-label Phase 1b/2 Study Assessing the Safety and Efficacy of Mitazalimab in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Gemcitabine (Primary) ; Irinotecan (Primary) ; Mitazalimab (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Pancreatic ductal carcinoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms OPTIMIZE-1
  • Sponsors Alligator Bioscience

Most Recent Events

  • 03 Jun 2025 Results presented in the Alligator Biosciences Media Release.
  • 03 Jun 2025 According to Alligator Biosciences media release, biomarker data from this trial were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • 23 May 2025 According to Alligator Biosciences media release, data from this trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top